Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report)’s stock price dropped 5.4% during trading on Tuesday . The company traded as low as $0.7144 and last traded at $0.7332. Approximately 170,162 shares were traded during trading, a decline of 99% from the average daily volume of 14,236,620 shares. The stock had previously closed at $0.7748.
Emerald Bioscience Trading Down 5.4%
The business’s fifty day simple moving average is $0.79. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.59 and a quick ratio of 3.59. The stock has a market cap of $196.55 million, a P/E ratio of -9.17 and a beta of 0.43.
About Emerald Bioscience
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
Read More
- Five stocks we like better than Emerald Bioscience
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
